New Strong Buy Stocks for September 17th

Zacks added Movado (MOV), MediaAlpha (MAX), MGIC Investment (MTG), Assembly Biosciences (ASMB), and Motorsport Games (MSGM) to its Rank #1 Strong Buy list. Current-year consensus EPS estimates rose 6.0% for Movado, 31.9% for MediaAlpha, 6.2% for MGIC, 20.0% for Assembly Biosciences, and 30.4% for Motorsport Games over the past 60 days. The updates are positive stock-specific estimate revisions but are unlikely to have broad market impact.

Analysis

This is a low-information, mechanically generated estimate-revision screen rather than an independent fundamental catalyst. The highest near-term reflexivity is likely in MAX, where estimate changes can attract momentum and quant flows into a relatively less-liquid, high-beta ad-tech/insurance-distribution name; the same dynamic raises gap and reversal risk if the next carrier or customer-acquisition data point disappoints. Treat any one-day strength as positioning-sensitive, not confirmation of durable earnings power.

MTG is the most institutionally actionable name, but its earnings trajectory is driven more by mortgage-credit normalization, new-insurance-written volumes, and reserve development than by a modest consensus revision. A stable labor market and subdued delinquency formation support buybacks and capital returns over the next 6-18 months; a sharp rise in unemployment, home-price declines, or a rate-driven collapse in purchase originations would reverse the setup. The relevant competitive read-through is to RDN and ESNT, where relative valuation and capital-return policies should determine the better long.

MOV's revisions are insufficient to overcome the structural issue: discretionary watches remain exposed to promotional intensity, retailer inventory discipline, and tariff/FX pressure. ASMB and MSGM should not be treated as earnings-revision trades: clinical-stage biotech value is dominated by trial/regulatory binary outcomes, while MSGM's small-cap liquidity makes consensus changes especially unreliable. The contrarian conclusion is that the screen may create a brief retail bid, but only MAX and MTG merit follow-up; neither warrants a market-open chase without volume and estimate-detail confirmation.

Key Decisions for Investors

• Watch, do not chase, MAX for 1-5 trading days: consider a tactical long only if it holds the post-screen high on at least 2x 20-day average volume and revised estimates are tied to disclosed operating drivers. Use a 7-10% stop; target 15-20% upside. Avoid the trade if gains occur on thin volume.
• Build a 3-6 month relative-value long MTG versus RDN only after comparing price-to-book, excess-capital distributions, and delinquency/reserve trends at the next earnings updates. Thesis is falsified by adverse reserve development or a sustained rise in mortgage delinquencies; target 10-15% relative return with a 5-7% relative stop.
• Avoid MOV ahead of the next earnings report unless management demonstrates full-price sell-through and inventory turns improving; a consensus revision alone does not offset likely gross-margin volatility. Prefer no position rather than a momentum long.
• Keep ASMB and MSGM outside fundamental book risk limits. Any exposure should be event-specific and sized as binary-risk capital, contingent on verified clinical milestones for ASMB or financing/liquidity disclosures for MSGM.